DCT

1:21-cv-01784

Janssen Pharma Inc v. Tolmar Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:21-cv-01784, D. Del., 12/21/2021
  • Venue Allegations: Venue is asserted in Delaware on the basis that all Defendant entities are incorporated under the laws of Delaware.
  • Core Dispute: This is a Hatch-Waxman action in which Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) to market a generic version of the antipsychotic drug Invega Sustenna® constitutes an act of infringement of a patent covering a specific dosing regimen.
  • Technical Context: The technology relates to methods for administering a long-acting injectable form of paliperidone palmitate, an antipsychotic medication used for treating schizophrenia, to rapidly achieve and maintain therapeutic plasma concentrations.
  • Key Procedural History: The complaint notes that this is the fourth Hatch-Waxman litigation involving the patent-in-suit. In the first case, a judge in the District of New Jersey concluded after a bench trial that the patent was not invalid, a finding that may have persuasive, though not necessarily preclusive, effect in this litigation. Two other cases are noted as pending.

Case Timeline

Date Event
2007-12-19 '906 Patent Priority Date
2016-09-13 '906 Patent Issue Date
2021-11-12 Date of Tolmar's Notice Letter regarding ANDA submission
2021-11-15 Date Plaintiffs received Tolmar's Notice Letter
2021-12-21 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

  • Patent Identification: U.S. Patent No. 9,439,906 ("the '906 Patent"), "Dosing Regimen Associated with Long Acting Injectable Paliperidone Esters," issued September 13, 2016. Compl. ¶23

The Invention Explained

  • Problem Addressed: The patent's background section describes the challenge of patient non-compliance with daily oral antipsychotic medications for mental illnesses like schizophrenia ʼ906 Patent, col. 2:50-54 While a long-acting injectable formulation of paliperidone palmitate can improve compliance, the patent explains that achieving a stable and therapeutically effective plasma concentration of the drug is complex and was found to be dependent on the site of injection (e.g., deltoid vs. gluteal muscle) ʼ906 Patent, col. 1:63 - col. 2:7
  • The Patented Solution: The '906 Patent discloses a specific dosing regimen designed to rapidly attain therapeutic plasma levels of paliperidone. The method involves administering two initial "loading doses" into the deltoid (shoulder) muscle, followed by subsequent, lower "maintenance doses" that can be administered in either the deltoid or gluteal (buttock) muscle ʼ906 Patent, abstract '906 Patent, col. 2:12-28 The specification explains that initial injections into the deltoid muscle result in a faster initial release of the drug compared to gluteal injections, allowing patients to reach a therapeutic concentration more quickly ʼ906 Patent, col. 5:3-7
  • Technical Importance: This specific initiation regimen allows for the benefits of a long-acting monthly injectable-improved patient compliance-while addressing the pharmacokinetic problem of slowly achieving a therapeutic effect ʼ906 Patent, col. 2:59-62

Key Claims at a Glance

  • The complaint asserts infringement of claims 1-21 Compl. ¶29 The lead independent claims appear to be claims 1 and 4.
  • Independent Claim 1 is a method claim comprising three key steps for treating schizophrenia or similar disorders:
    • Administering a first loading dose of about 150 mg-eq. of paliperidone palmitate intramuscularly into the deltoid muscle on the first day of treatment.
    • Administering a second loading dose of about 100 mg-eq. of paliperidone palmitate intramuscularly into the deltoid muscle between the 6th and 10th day of treatment.
    • Administering a first maintenance dose of about 25 mg-eq. to about 150 mg-eq. into the deltoid or gluteal muscle approximately one month (±7 days) after the second loading dose.
  • Independent Claim 4 is similar to claim 1 but more narrowly specifies that the second loading dose is administered on the eighth day of treatment.
  • By asserting claims 1-21, the complaint implicitly includes all dependent claims, which add further limitations regarding, for example, subsequent maintenance doses and specific patient populations (e.g., renally impaired patients).

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is Defendants' proposed generic paliperidone palmitate extended-release injectable suspension product, which is the subject of Abbreviated New Drug Application ("ANDA") No. 211995 Compl. ¶10 Compl. ¶30

Functionality and Market Context

  • The product is a proposed generic equivalent of Plaintiffs' Invega Sustenna® brand product Compl. ¶2
  • The infringement action was triggered by the filing of the ANDA under the Hatch-Waxman Act, which is a statutory act of infringement intended to resolve patent disputes prior to the launch of a generic drug Compl. ¶2 Compl. ¶15
  • The complaint alleges that Defendants' proposed product is intended for the same indications as Invega Sustenna®, namely the treatment of schizophrenia and schizoaffective disorder Compl. ¶26
  • The ANDA seeks approval to market the product in multiple dosage strengths, including 39 mg, 78 mg, 117 mg, 156 mg, and 234 mg, which correspond to the dosage strengths of the branded product Compl. ¶30
  • The core of the infringement allegation is that Defendants' proposed labeling for the generic product will instruct physicians and patients to administer the drug according to the patented regimen, as generic drug labels are generally required to mirror the label of the brand-name drug they copy Compl. ¶39

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide a claim chart or a detailed technical breakdown of the infringement allegations. Such detail is not required at the pleading stage, particularly in Hatch-Waxman cases. The infringement theory is based on Defendants' submission of ANDA No. 211995, which constitutes a technical act of infringement under 35 U.S.C. § 271(e)(2) Compl. ¶37

The complaint alleges that Defendants' proposed generic product, if approved and marketed, will be administered according to its label, and that this use will infringe claims 1-21 of the '906 Patent, either literally or under the doctrine of equivalents Compl. ¶36 The basis for this allegation is the requirement that a generic drug's label must be the same as the corresponding brand-name drug's label Compl. ¶39 Therefore, Plaintiffs' infringement theory rests on the premise that the Invega Sustenna® label, which Defendants' product will allegedly copy, directs users to perform the patented dosing method.

  • Identified Points of Contention:
    • Validity: The primary battleground in this case will likely be the validity of the '906 Patent. Defendants' ANDA filing included a Paragraph IV certification, asserting that the patent is "invalid, unenforceable, and/or not infringed" Compl. ¶31 A key question will be whether Defendants can present invalidity arguments (e.g., based on obviousness over prior art) that are more persuasive than those that were previously rejected in the litigation involving Teva Pharmaceuticals Compl. ¶27
    • Infringement: The infringement dispute will likely focus on whether the instructions in Defendants' proposed label will necessarily lead to infringement. A potential question for the court is whether the label directs administration of the specific two-step loading dose regimen in the deltoid muscle as required by the independent claims, or if it offers alternative, non-infringing dosing options that a physician could choose.

V. Key Claim Terms for Construction

The complaint does not identify any specific claim terms as likely to be in dispute. However, based on the claim language and the technical context, the following terms may be central to the case.

  • The Term: "a month (±7 days)"

  • Context and Importance: This term, appearing in independent claim 1, defines the timing for the first maintenance dose. The scope of this temporal limitation is critical for determining whether a particular dosing schedule constitutes literal infringement. Practitioners may focus on this term because if a defendant's proposed label provides for or allows dosing outside this specific window, it could form the basis of a non-infringement defense.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification uses more general phrases like "approximately monthly" and provides an example of "once every four weeks" '906 Patent, col. 3:8 '906 Patent, col. 5:4-5, which a party could argue supports a more flexible interpretation beyond a strict 21-35 day window.
    • Evidence for a Narrower Interpretation: The claim language itself provides an explicit numerical range. A party arguing for a narrower construction could assert that "(±7 days)" was a deliberate choice to provide a precise and limited definition, superseding the more general language in the specification.

  • The Term: "about [dosage] mg-eq." (e.g., "about 150 mg-eq.")

  • Context and Importance: This term qualifies the specific quantities of the drug to be administered in the loading and maintenance doses. The interpretation of "about" defines the permissible range around the specified dosages.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The use of "about" itself implies some degree of variance. A party might argue that the term should be interpreted functionally to cover dosages that achieve a similar pharmacokinetic profile, pointing to the patent's overall goal of achieving a therapeutic plasma concentration '906 Patent, col. 2:4-7
    • Evidence for a Narrower Interpretation: The specification provides specific dose ranges in embodiments, such as "from about 100 mg-eq. to about 150 mg-eq. of paliperidone" '906 Patent, col. 2:15-16 A party could argue these explicit ranges limit the interpretation of "about" when applied to a single value, suggesting it should only cover minor variations or measurement tolerances.

VI. Other Allegations

  • Indirect Infringement: The complaint pleads both induced and contributory infringement.
    • Inducement: The inducement allegation is based on the claim that Defendants' product labeling will actively instruct and encourage physicians to administer the drug in a manner that directly infringes the '906 Patent Compl. ¶39
    • Contributory: The contributory infringement allegation is based on the claim that Defendants' product is a material part of the patented method, is not a staple article of commerce with substantial non-infringing uses, and is specifically designed for an infringing use Compl. ¶40
  • Willful Infringement: While the complaint does not contain a formal count for "willful infringement," it alleges that Defendants have "actual knowledge of the '906 Patent" from at least the time of their notice letter Compl. ¶35 It further characterizes the case as "exceptional" and seeks an award of attorneys' fees under 35 U.S.C. § 285 Compl. ¶43 Compl., Prayer F, which is the relief typically associated with findings of willful infringement or other litigation misconduct.

VII. Analyst's Conclusion: Key Questions for the Case

This Hatch-Waxman litigation will likely center on the following key questions:

  • A central question will be one of validity and preclusion: Considering a prior judicial decision upheld the validity of the '906 Patent against a different challenger, can Tolmar present a sufficiently novel or persuasive invalidity argument to avoid a similar outcome and prove by clear and convincing evidence that the patent's claims are invalid?
  • The core infringement issue will be one of induced infringement by labeling: Does Tolmar's proposed product label-which is expected to copy the label of Invega Sustenna®-necessarily instruct physicians to follow the patented two-step deltoid loading dose regimen, or does it provide for clinically relevant, alternative non-infringing methods of administration that would defeat a claim of inducement?
  • A determinative issue may be one of obviousness: Can Tolmar demonstrate that the claimed dosing regimen-specifically the use of two initial deltoid injections to achieve a rapid therapeutic concentration-would have been obvious to a person of ordinary skill in the art at the time of the invention, based on the known pharmacokinetic properties of deltoid versus gluteal injections and existing knowledge of loading dose strategies?
Loading Complaint